Complete financial analysis of Avid Bioservices, Inc. (CDMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avid Bioservices, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Renewi plc (RWI.AS) Income Statement Analysis – Financial Results
- PageGroup plc (PAGE.L) Income Statement Analysis – Financial Results
- Unicycive Therapeutics, Inc. (UNCY) Income Statement Analysis – Financial Results
- Ono Pharmaceutical Co., Ltd. (OPHLF) Income Statement Analysis – Financial Results
- Twin Butte Energy Ltd. (TBTEF) Income Statement Analysis – Financial Results
Avid Bioservices, Inc. (CDMO)
About Avid Bioservices, Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.91M | 149.27M | 119.60M | 95.87M | 59.70M | 53.60M | 53.62M | 57.63M | 44.69M | 26.78M | 22.40M | 21.68M | 15.23M | 13.49M | 27.94M | 18.15M | 6.09M | 3.71M | 3.19M | 4.96M | 3.31M | 3.92M | 3.77M | 979.00K | 1.00K | 100.00K | 500.00K | 300.00K | 3.10M | 100.00K |
| Cost of Revenue | 132.59M | 117.79M | 82.95M | 66.56M | 55.77M | 46.38M | 56.55M | 38.26M | 22.97M | 15.59M | 13.11M | 12.60M | 10.15M | 7.30M | 8.72M | 9.06M | 4.80M | 3.30M | 3.30M | 4.40M | 2.21M | 2.86M | 0.00 | -412.00K | -516.00K | 3.50M | -700.00K | -300.00K | 0.00 | 1.00M |
| Gross Profit | 7.32M | 31.48M | 36.65M | 29.31M | 3.93M | 7.22M | -2.92M | 19.37M | 21.72M | 11.19M | 9.29M | 9.09M | 5.08M | 6.20M | 19.23M | 9.09M | 1.29M | 412.00K | -104.00K | 558.00K | 1.10M | 1.06M | 3.77M | 1.39M | 517.00K | -3.40M | 1.20M | 600.00K | 3.10M | -900.00K |
| Gross Profit Ratio | 5.23% | 21.09% | 30.64% | 30.57% | 6.59% | 13.48% | -5.45% | 33.61% | 48.61% | 41.78% | 41.48% | 41.91% | 33.35% | 45.92% | 68.81% | 50.06% | 21.16% | 11.11% | -3.26% | 11.25% | 33.25% | 27.06% | 100.00% | 142.08% | 51,700.00% | -3,400.00% | 240.00% | 200.00% | 100.00% | -900.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.30M | 59.53M | 43.00M | 27.72M | 24.31M | 35.69M | 29.46M | 24.66M | 18.42M | 18.28M | 15.88M | 12.42M | 11.16M | 9.67M | 8.74M | 13.51M | 7.38M | 8.08M | 8.80M | 7.60M | 30.00M | 1.70M | 0.00 |
| General & Administrative | 25.20M | 27.18M | 20.63M | 16.76M | 14.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Selling & Marketing | 800.00K | 700.00K | 600.00K | 300.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 19.33M | 18.55M | 18.69M | 17.27M | 13.13M | 11.46M | 11.42M | 8.18M | 6.98M | 7.15M | 6.45M | 6.56M | 5.10M | 4.23M | 2.99M | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Other Expenses | 1.00 | 1.00M | -81.00K | 133.00K | 355.00K | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| Operating Expenses | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 47.63M | 78.08M | 61.69M | 45.00M | 37.44M | 47.15M | 40.88M | 32.84M | 25.40M | 25.43M | 22.32M | 18.98M | 16.26M | 13.90M | 11.73M | 15.98M | 11.60M | 12.83M | 16.00M | 12.80M | 33.60M | 2.80M | 900.00K |
| Cost & Expenses | 158.59M | 145.67M | 104.18M | 83.63M | 70.29M | 59.23M | 73.00M | 85.89M | 101.05M | 77.28M | 58.11M | 50.04M | 57.30M | 48.18M | 41.56M | 34.47M | 30.23M | 25.62M | 22.28M | 20.66M | 16.11M | 14.59M | 15.98M | 11.19M | 12.31M | 19.50M | 12.10M | 33.30M | 2.80M | 1.90M |
| Interest Income | 0.00 | 2.60M | 2.68M | 133.00K | 474.00K | 282.00K | 102.00K | 108.00K | 722.00K | 142.00K | 349.00K | 322.00K | 41.00K | 1.05M | 116.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.34M | 2.60M | 2.68M | 1.16M | 8.00K | 11.00K | 27.00K | 7.00K | 14.00K | 1.00K | 5.00K | 54.00K | 90.00K | 516.00K | 997.00K | 408.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.11M | 7.21M | 4.48M | 3.45M | 3.09M | 2.75M | 2.56M | 2.46M | 1.54M | 1.04M | 986.00K | 1.09M | 908.00K | 652.00K | 1.12M | 503.00K | 486.00K | 866.00K | 415.00K | 325.00K | 2.19M | 1.38M | 424.00K | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| EBITDA | -11.48M | 10.91M | 19.90M | 15.70M | -7.38M | -2.59M | -16.82M | 3.76M | 5.02M | -49.32M | -34.37M | -28.64M | -41.12M | -32.98M | -13.05M | -15.61M | -23.65M | -21.04M | -18.67M | -15.38M | -10.61M | -9.29M | -11.79M | -9.80M | -11.79M | -18.50M | -11.30M | -32.90M | 500.00K | -1.60M |
| EBITDA Ratio | -8.21% | 3.08% | 12.83% | 12.91% | -17.14% | -10.49% | -35.95% | -48.85% | -121.07% | -184.15% | -153.44% | -129.27% | -276.18% | -257.09% | -44.72% | -87.12% | -388.22% | -567.53% | -623.14% | -310.12% | -320.19% | -236.90% | -313.17% | -1,000.20% | -960,400.00% | -18,800.00% | -2,180.00% | -10,900.00% | 22.58% | 3,400.00% |
| Operating Income | -18.68M | -2.61M | 10.86M | 8.92M | -10.59M | -5.62M | -20.64M | -28.26M | -56.36M | -50.50M | -35.71M | -28.35M | -42.07M | -34.69M | -13.61M | -16.32M | -24.14M | -21.91M | -19.08M | -15.70M | -12.80M | -10.67M | -12.22M | -10.21M | -12.31M | -19.40M | -11.60M | -33.00M | 300.00K | -1.80M |
| Operating Income Ratio | -13.35% | -1.75% | 9.08% | 9.31% | -17.73% | -10.49% | -38.49% | -49.04% | -126.12% | -188.56% | -159.39% | -130.76% | -276.18% | -257.09% | -48.72% | -89.89% | -396.19% | -590.88% | -597.65% | -316.68% | -386.12% | -272.12% | -324.43% | -1,043.21% | -1,231,000.00% | -19,400.00% | -2,320.00% | -11,000.00% | 9.68% | -1,800.00% |
| Total Other Income/Expenses | -8.25M | -2.01M | -2.76M | -1.03M | 119.00K | 282.00K | 75.00K | 101.00K | 708.00K | 141.00K | 344.00K | -1.43M | -49.00K | 536.00K | 13.61M | 16.32M | 964.00K | 1.11M | 2.02M | 252.00K | -1.55M | 0.00 | 0.00 | -9.00K | -2.19M | 499.00K | 0.00 | 0.00 | -200.00K | -5.00M |
| Income Before Tax | -26.93M | 2.00M | 12.66M | 11.21M | -10.47M | -5.34M | -20.56M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -34,151.00B | -34,151.00B | -14,494.00B | -16,524.00B | 0.00 | 0.00 | -17.85M | 0.00 | -14.35M | 0.00 | 0.00 | -10.22M | -14.50M | -19.00M | 0.00 | 0.00 | 100.00K | -6.80M |
| Income Before Tax Ratio | -19.25% | 1.34% | 10.59% | 11.70% | -17.53% | -9.96% | -38.35% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -224,190,901.33% | -253,120,367.63% | -51,869,877.97% | -91,036,306.54% | 0.00% | 0.00% | -559.16% | 0.00% | -432.86% | 0.00% | 0.00% | -1,044.13% | -1,450,000.00% | -19,000.00% | 0.00% | 0.00% | 3.23% | -6,800.00% |
| Income Tax Expense | 113.83M | 1.44M | -115.01M | -2.29M | -3.21M | -284.00K | -1.29M | -2.36M | 722.00K | 142.00K | 349.00K | -1.03M | 536.00B | 536.00B | -881.00B | -208.00B | -964.00K | -1.11M | -2.02M | -252.00K | 0.00 | 889.00K | -500.00K | -678.00K | 2.20M | 100.00K | 200.00K | 200.00K | 0.00 | 5.10M |
| Net Income | -140.75M | 560.00K | 127.67M | 11.21M | -7.26M | -4.22M | -21.81M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -42.12M | -34.15M | -14.49M | -16.52M | -23.18M | -20.80M | -17.06M | -15.45M | -14.35M | -11.56M | -11.72M | -9.54M | -14.51M | -19.50M | -11.80M | -33.20M | 300.00K | -6.90M |
| Net Income Ratio | -100.60% | 0.38% | 106.75% | 11.70% | -12.15% | -7.86% | -40.68% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -276.50% | -253.12% | -51.87% | -91.04% | -380.37% | -560.84% | -534.33% | -311.60% | -432.86% | -294.80% | -311.15% | -973.95% | -1,451,400.00% | -19,500.00% | -2,360.00% | -11,066.67% | 9.68% | -6,900.00% |
| EPS | -2.23 | 0.01 | 2.08 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| EPS Diluted | -2.23 | 0.01 | 1.81 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| Weighted Avg Shares Out | 63.20M | 62.27M | 61.48M | 58.22M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
| Weighted Avg Shares Out (Dil) | 63.20M | 63.78M | 70.47M | 59.43M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder...
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $CDMO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avid Bioservices, Inc. (“Avid Bioservices” or “the Company”) (NASDAQ: CDMO). Investors who purchased Avid Bioservices securities are encouraged to obtain additional...
CDMO LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation – CDMO
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Avid Bioservices, Inc. (NASDAQ: CDMO) resulting from allegations that Avid Bioservices may have issued materially misleading...
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Thursday after the contract development and manufacturing company announced the pricing of a private placement. The private placement includes 7.00% Convertible Senior Notes due 2029 with an aggregate principal amount of $160 million.
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029...
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount...
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced...
Avid Bioservices: Don't Miss The Bigger Picture
Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400 million, with expected adjusted EBITDA margins in the low to mid...
Why Is Avid Bioservices (CDMO) Stock Down 18% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Friday following the release of its earnings report for its fiscal second quarter of 2024. Avid Bioservices reported adjusted earnings per share of -12 cents alongside revenue of $25.4 million.
CDMO Stock Earnings: Avid Bioservices Misses EPS, Misses Revenue for Q2 2024
Avid Bioservices (NASDAQ: CDMO ) just reported results for the second quarter of 2024. Avid Bioservices reported earnings per share of -12 cents.
Source: https://incomestatements.info
Category: Stock Reports